Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis

Background and aimHigh-grade B cell lymphomas with concomitant MYC and BCL2 and/or BCL6 rearrangements (HGBCL-DH/TH) have a poor prognosis when treated with the standard R-CHOP-like chemoimmunotherapy protocol. Whether this can be improved using intensified regimens is still under debate. However, due to the rarity of HGBCL-DH/TH there are no prospective, randomized controlled trials (RCT) available. Thus, with this systematic review and meta-analysis we attempted to compare survival in HGBCL-DH/TH patients receiving intensified vs. R-CHOP(-like) regimens.MethodsThe PubMed and Web of Science databases were searched for original studies reporting on first-line treatment in HGBCL-DH/TH patients from 08/2014 until 04/2022. Studies with only localized stage disease, ≤10 patients, single-arm, non-full peer-reviewed publications, and preclinical studies were excluded. The quality of literature and the risk of bias was assessed using the Methodological Index for Non-Randomized Studies (MINORS) and National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Random-effect models were used to compare R-CHOP-(like) and intensified regimens regarding 2-year overall survival (2y-OS) and 2-year progression-free survival (2y-PFS).ResultsAltogether, 11 retrospective studies, but no RCT, with 891 patients were included. Only four studies were of good quality based on aforementioned criteria. Intensified treatment could improve 2y-OS (hazard ratio [HR]=0.78 [95% confidence interval [CI] 0.63-0.96]; p=0.02) as well as 2y-PFS (HR=0.66 [95% CI 0.44-0.99]; p=0.045).ConclusionsThis meta-analysis indicates that intensified regimens could possibly improve 2y-OS and 2y-PFS in HGBCL-DH/TH patients. However, the significance of these results is mainly limited by data quality, data robustness, and its retrospective nature. There is still a need for innovative controlled clinical trials in this difficult to treat patient population.Systematic review registrationhttps://www.crd.york.ac.uk/prospero, identifier CRD42022313234

Bismuth oxyhalides for NOx degradation under visible light: the role of the chloride precursor

ABSTRACT: Photocatalysis is a green technology for tackling water and air contamination. A valid alternative to the most exploited photocatalytic material, TiO2, is bismuth oxyhalides, which feature a wider bandgap energy range and use visible radiation to attain photoexcitation. Moreover, their layered structure favors the separation of photogenerated electron–hole pairs, with an enhancement in photocatalytic activity. Controlled doping of bismuth oxyhalides with metallic bismuth nanoparticles allows for further boosting of the performance of the material. In the present work, we synthesized Y%Bi-doped BiO(Cl0.875Br0.125) (Y = 0.85, 1, 2, 10) photocatalysts, using cetyltrimethylammonium bromide as the bromide source and varying the chloride source to assess the impact that both length and branching of the hydrocarbon chain might have on the framing and layering of the material. A change in the amount of the reducing agent NaBH4 allowed tuning of the percentage of metallic bismuth. After a thorough characterization (XRPD, SEM, TEM, UV-DRS, XPS), the photocatalytic activity of the catalysts was tested in the degradation of NOx under visible light, reaching a remarkable 53% conversion after 3 h of illumination for the material prepared using cetylpyridinium chloride

Bismuth Oxyhalides for NOx Degradation under Visible Light: The Role of the Chloride Precursor

Photocatalysis is a green technology for tackling water and air contamination. A valid alternative to the most exploited photocatalytic material, TiO2, is bismuth oxyhalides, which feature a wider bandgap energy range and use visible radiation to attain photoexcitation. Moreover, their layered structure favors the separation of photogenerated electron–hole pairs, with an enhancement in photocatalytic activity. Controlled doping of bismuth oxyhalides with metallic bismuth nanoparticles allows for further boosting of the performance of the material. In the present work, we synthesized Y%Bi-doped BiO(Cl0.875Br0.125) (Y = 0.85, 1, 2, 10) photocatalysts, using cetyltrimethylammonium bromide as the bromide source and varying the chloride source to assess the impact that both length and branching of the hydrocarbon chain might have on the framing and layering of the material. A change in the amount of the reducing agent NaBH4 allowed tuning of the percentage of metallic bismuth. After a thorough characterization (XRPD, SEM, TEM, UV-DRS, XPS), the photocatalytic activity of the catalysts was tested in the degradation of NOx under visible light, reaching a remarkable 53% conversion after 3 h of illumination for the material prepared using cetylpyridinium chloride

ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial

Background. The identification of germline mutations in familial leukemia predisposition genes by next generation sequencing is of pivotal importance. Lately, some “blend pedigrees” characterized by both solid and hematologic malignancies have been described. Some genes were recognized as related to this double predisposition, while the involvement of others is still a matter of debate. ETV6 was associated with hematologic malignancies, in particular myeloid malignancies, and recently described as mutated also in oncologic patients. No clear evidences in its involvement in blend pedigrees are known. Case Presentation. We present our recent experience in the identification of an ETV6-mutated “blend pedigree,” suggesting the involvement of ETV6 in the predisposition to both solid and hematologic neoplasia. The pedigree recognition started with a MDS case enrolled in the NEXT-Famly protocol. The patient presented 9 relatives affected by solid tumors and hematological malignancies. Following the clinical trial protocol, the patient underwent NGS analysis, which confirmed the presence of a mutation on the noncoding region of ETV6 both on tumor and on germline DNA. The mutation resulted was shared by the still alive affected relatives. Conclusion. This evidence supports the involvement of ETV6 in the predisposition to both solid and hematologic neoplasia and the importance of the investigation of the noncoding regions of the genes as recently suggested by different expert groups